Intra-Cellular Therapies Inc. (ITCI)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
ITCI Chart
ITCI Q4 Loss Wider Than Expected, Revenues Top on Higher Caplyta Sales
Intra-Cellular reports mixed fourth-quarter 2024 results, wherein earnings miss estimates but revenues beat the same driven by strong Caplyta sales.
Intra-Cellular Therapies (ITCI) Reports Q4 Loss, Tops Revenue Estimates
Intra-Cellular Therapies (ITCI) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.05. This compares to loss of $0.30 per share a year ago.
Intra-Cellular Therapies Stock Up 34% on J&J's $14.6B Buyout Offer
JNJ is set to acquire ITCI for $132 per share in cash. The transaction is likely to close before this year's end.
Intra-Cellular Therapies Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| MC Mike Clark Cassady Schiller Wealth Management LLC | 13 | $1.09 | $1.04 | -$0.05 | -4.59% |
Intra-Cellular Therapies Inc. (ITCI) FAQ
What does "Delisted" mean?
What was the last recorded dividend?
How long did the company pay dividends?
Were there any stock splits?
What was the last known trading price?
Intra-Cellular Therapies Inc. Profile
| - Industry | - Sector | Dr. Sharon Mates Ph.D. CEO | NASDAQ (NGS) Exchange | 46116X101 CUSIP |
| US Country | 610 Employees | - Last Dividend | - Last Split | 7 Jan 2014 IPO Date |
Overview
Intra-Cellular Therapies, Inc. is a forward-looking biopharmaceutical company engaged in the innovative realm of developing small molecule drugs aimed at fulfilling the unmet medical needs within neuropsychiatric and neurological disorders. By focusing on the intricate mechanisms of intracellular signaling within the central nervous system (CNS), the company pioneers in addressing some of the most challenging conditions affecting mental health today. Founded in 2002 and based in New York, New York, Intra-Cellular Therapies is at the forefront of bringing novel treatments from the laboratory to the clinic, with an emphasis on the U.S. market.
Products and Services
- CAPLYTA (Lumateperone) - Currently offered for the treatment of schizophrenia and bipolar depression in adults, CAPLYTA represents Intra-Cellular Therapies’ commitment to addressing severe mental illnesses with a need for better treatment options.
- Lumateperone - Beyond its approved uses, Lumateperone is in a Phase 3 clinical trial stage aiming to expand its application to treat various depressive disorders. This exploration highlights the company’s continuous efforts to broaden the therapeutic utility of its lead compound.
- Lenrispodun (ITI-214) - In development for the treatment of Parkinson's disease, CNS conditions, and other disorders, Lenrispodun exemplifies the company’s venture into addressing neurological disorders with significant unmet needs.
- ITI-1284 - Targeted for the treatment of neuropsychiatric disorders and behavioral disturbances in dementia, ITI-1284 reflects Intra-Cellular Therapies’ dedication to combating the challenges faced by aging populations.
- ITI-333 - This compound is under development for an array of conditions, including substance use disorders, pain, and psychiatric comorbidities such as depression, anxiety, and sleep disorders. ITI-333 embodies the company’s holistic approach to tackling complex, intertwined health issues.
